Gamida Cell Company Profile
Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companyâs pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers such as leukemia and lymphoma, solid tumors, autoimmune diseases, metabolic diseases and non-malignant hematological diseases. Gamida Cellâs therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cellâs current shareholders include: Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: www.gamida-cell.com.
News Articles
Gamida Cell to meet FDA, EMA over stem cell treatment
JERUSALEM, April 11 (Reuters) - Gamida Cell, a developer of stem cell therapy products, plans to meet the U.S. Food and Drug Administration and European Medicines Agency in the coming months to discus...
Gamida reports StemEx data for hematologic malignancies
Gamida Cell Ltd. (Jerusalem, Israel) said StemEx met the primary endpoint of improving the mortality rate at 100 days post-transplantation vs. a historical control group in the Phase II/III ExCell tri...
Gamida completes enrolment in Phase I/II study of NiCord
Gamida Cell has finished enrolment in Phase I/II study of NiCord, which is based on Gamida Cell's proprietary NAM technology, for haematological malignancies (HM or blood cancer).
Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product NiCord for ...
Gamida Cell’s flagship product StemEx® remains on course: Phase III study results in Q4/12
Gamida Cell's StemEx Achieves Primary Endpoint in Phase II/III Clinical Study
JERUSALEM--(BUSINESS WIRE)--Feb 4, 2013 - Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compar...
Study results presented in an Oral Presentation at the 2013 BMT Tandem Meetings in Salt Lake City, Utah JERUSALEM--(BUSINESS WIRE)--Feb 14, 2013 - Gamida Cell announced today the successful results of...
Gamida Cells StemEx Achieves Primary Endpoint in Phase II/III Clinical Study
Gamida proceeds with study of experimental blood cancer therapy
Gamida Cell completed patient enrollment for a Phase I/II trial of the cell graft product NiCord as a substitute experimental -More-
Drugs and Medications
Drug Facts
Drug Facts
Alimta [Eli Lilly and Company]
These highlights do not include all the information needed to use ALIMTA safely and effectively. See full prescribing information for ALIMTA. ALIMTA (pemetrexed for injection) Lyophilized Powder, for...
Hycamtin [GlaxoSmithKline LLC]
These highlights do not include all the information needed to use HYCAMTIN safely and effectively. See full prescribing information for HYCAMTIN. HYCAMTIN (topotecan) CapsulesInitial U.S. Approval: 19...
PubMed Articles
None
Clinical Trials
A Study for Patients With Non-Hodgkin's Lymphomas
In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and A...
Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease
To determine the retinal and choroidal thickness in patients with sickle cell disease compared to age, race matched population without sickle cell disease to allow a better understanding o...
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymph...
To compare the anti-tumor activity of everolimus and sunitinib in subjects with mRCC with non-clear cell pathology.
The purpose of this trial is to determine if patients with hematologic diseases who have a HLA 6/6 matched related donor and are not eligible for a standard myeloablative stem cell transpl...
Companies
Gamida Cell is developing expanded stem cell therapies for the treatment of such illnesses as blood cancers, cardiac disease and diabetes. The Company is dedicated to making a significant difference...
Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companyâs pipel...
Cell Press, an imprint of Elsevier, is committed to improving scientific communication through the publication of exciting research and reviews. Each of our titles is viewed as a must-read by the...
Cell Essentials provides contract cell biology-based services facilitating the creation of reagents for use in diagnostics and drug discovery as well as basic research. Major services include the deve...
One Cell Systems is developing and marketing a family of single cell assays that rely on microencapsulation and flow cytometry. Technology underlying these products has been developed internally and l...
More Information about "Gamida Cell" on BioPortfolio
We have published hundreds of Gamida Cell news stories on BioPortfolio along with dozens of Gamida Cell Clinical Trials and PubMed Articles about Gamida Cell for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Gamida Cell Companies in our database. You can also find out about relevant Gamida Cell Drugs and Medications on this site too.
